**Name of Journal:** *World Journal of Obstetrics and Gynecology*

**Manuscript NO:** 78820

**Manuscript Type:** CASE REPORT

**Primary peritoneal hemangioendothelioma simulating an ovarian cyst: A case report and review of literature**

Spinelli C *et al.* Peritoneal hemangioendothelioma

Claudio Spinelli, Marco Ghionzoli, Silvia Strambi

**Claudio Spinelli, Marco Ghionzoli, Silvia Strambi,** Pediatric and Adolescent Surgery Division, Department of Surgical, Medical, Molecular Pathology and of the Critic Area, University of Pisa, Pisa 56126, Italy

**Author contributions:** Spinelli C conceived and designed the analysis; Strambi S collected the data and performed the analysis; Spinelli C, Ghionzoli M, Strambi S, contributed data or analysis tools and wrote the paper.

**Corresponding author: Claudio Spinelli, MD, Full Professor, Professor, Surgeon,** Pediatric and Adolescent Surgery Division, Department of Surgical, Medical, Molecular Pathology and of the Critic Area, University of Pisa, Via Paradisa 2, Pisa 56126, Italy. claudio.spinelli@unipi.it

**Received:** July 18, 2022

**Revised:** August 5, 2022

**Accepted:** November 23, 2022

**Published online:** November 29, 2022

**Abstract**

BACKGROUND

Epithelioid hemangioendothelioma (EHE) is an extremely rare tumor with a prevalence of one in a million and a very heterogenous spectrum of disease that varies from an indolent to a metastasizing aggressive disease, with the liver, lung and bone being the primarily involved organs. Peritoneal forms of EHE are even rare, and only 12 cases have been reported to date in the literature.

CASE SUMMARY

A 66-year-old female came to our attention complaining low abdominal and perineal pain. Magnetic resonance imaging examination showed a 52 mm × 58 mm × 32 mm cystic mass with some smooth septa, simulating an ovarian cyst. Explorative laparoscopy demonstrated the presence of a peritoneal mass of augmented consistency connected with a sigmoid epiploic appendix in the right side of the Pouch of Douglas, that was surgically removed. Histological examination revealed a primitive peritoneal hemangioendothelioma. The patient easily recovered from surgery with no residual pain or discomfort. She is regularly attending a 3-years follow-up that is negative for local recurrence of disease or distant metastases.

CONCLUSION

Peritoneal form of EHE often simulates masses of other nature, as in our case. Given its unspecific clinical and radiological presentation, patients are often forced to a large series of tests and examinations before reaching a definitive diagnosis, that can only histologically made. The possibility of EHE should always be considered in case of unexplained chronic abdominal pain associated to a non-specific mass.

**Key Words:** Epithelioid hemangioendothelioma; Peritoneal hemangioendothelioma; Peritoneal tumor; Hemangioendothelioma; Unusual presentation; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Spinelli C, Ghionzoli M, Strambi S. Primary peritoneal hemangioendothelioma simulating an ovarian cyst: A case report and review of literature. *World J Obstet Gynecol* 2022; 11(4): 40-46

**URL**: https://www.wjgnet.com/2218-6220/full/v11/i4/40.htm

**DOI**: https://dx.doi.org/10.5317/wjog.v11.i4.40

**Core Tip:** In this article we describe the case of a woman of middle age who came to our observation for chronic abdominal pain. Diagnostic examinations showed a mass of undefined nature which simulated an ovarian cyst due to its pelvic position and its morphological features. Histological examination revealed a primary peritoneal hemangioendothelioma, which is an extremely rare form of epithelioid hemangioendothelioma, with only 12 cases reported in the literature to date. Epithelioid hemangioendothelioma has a very heterogenous spectrum of disease that varies from an indolent to a metastasizing aggressive disease, with the liver, lung and bone being the primarily involved organs.

**INTRODUCTION**

Epithelioid hemangioendothelioma (EHE) is an extremely rare neoplasm with a prevalence of 1:1000000[1], and as such, the current reported cases are limited to single reports and series aimed to better describe the clinical, pathologic, and molecular characteristics, as well as the best treatment approaches[2].

The spectrum of disease is very heterogenous and varies greatly between an indolent disease and a metastasizing aggressive disease, with the liver, lung and bone being the primarily involved organs[2]. However, EHE can occur in various anatomical sites such as retroperitoneum, ovary, pleura, lymph nodes and subcutaneous fat[1], making the clinical presentation very unspecific and the diagnosis often challenging. Given its heterogeneity, also the prognosis differs from one patient to another. Traditionally, risk factors for worse outcomes have comprised anemia and weight loss, as well as pulmonary symptoms such as pleurisy[3,4]. An increased mitotic activity and size have also been seen to be correlated with a worse prognosis[5]. Peritoneal forms of EHE are seldom described: to date only 12 other cases have been reported (Table 1)[6-12].

In this article we describe the case of a woman of middle age who came to our observation for abdominal pain, which was then discovered to be caused by a primary peritoneal hemangioendothelioma simulating an ovarian cyst.

**CASE PRESENTATION**

***Chief complaints***

A 66-year-old female with history of right mammalian quadrantectomy followed by radiotherapy for breast cancer came to our attention complaining low abdominal and perineal pain.

***History of present illness***

A recent routinely gynecological examination showed the presence at ultrasound of a small fluid collection in the Douglas pouch, with normal genital organs.

***History of past illness***

There is no history of past illness.

***Personal and family history***

There is no personal and family history.

***Physical examination***

The physical examination and the laboratory blood tests including tumor markers levels (CEA, Ca 19.9, Ca 125, aFP) were all normal.

***Laboratory examinations***

Does not involve laboratory examination.

***Imaging examinations***

Colonoscopy was completely negative while abdominal contrast-enhancement computed tomography (CT) examination confirmed the presence of a 76 mm × 52 mm fluid collection with some incomplete septa located in the right paramedian region of the Douglas pouch with mild delayed enhancement. The patient was then submitted to an abdominal magnetic resonance imaging which detected the presence of a 52 mm × 58 mm × 32 mm cystic mass with some smooth septa, simulating an ovarian cyst (Figure 1).

**FINAL DIAGNOSIS**

Considering the impossibility to discriminate the nature of the mass, we decided to perform a diagnostic abdominal explorative laparoscopy.

**TREATMENT**

During surgery, a peritoneal mass of augmented consistency strictly connected with a sigmoid epiploic appendix was found in the right side of the Pouch of Douglas and surgically removed. Extemporaneous histological examination revealed the presence of a focal central area of necrosis and blood vessels of various dimension, intense chronic inflammation consisting of lympho-monocytoid cells, plasma-cells and hystiocytes filled with hemosiderin, without atypic cells. No further surgical resection was therefore performed. Post-operative course was deemed uneventful, and the patient was discharged on 3rd post-operative day.

**OUTCOME AND FOLLOW-UP**

Definitive histological and immunohistochemistry examination demonstrated a primitive peritoneal hemangioendothelioma which consisted of a vascularized proliferation of blood vessels associated with involutive aspects and necrosis (Figure 2). A regular 3-years scheduled ultrasound and abdominal CT scan follow-up has shown neither local recurrence of the disease nor distant metastases. Currently, the patient is in good clinical condition without any residual pain or discomfort. Written informed consent was obtained from the patient for the anonymous publication of the case.

**DISCUSSION**

EHE is defined as a localized intrusive vascular tumor which originates from endothelial cells. It may originate from any anatomical site and can metastasize to soft tissues, bones and viscera[13]. The first description of EHE comes from Dail and Liebow in 1975: They defined it as an intravascular bronchoalveolar tumor involving the lungs[14]. The term “epithelioid hemangioendothelioma” was then coined by Weiss and Enzinger in 1982[15], to highlight a neoplasm made of “rounded or slightly spindled eosinophilic endothelial cells that grows in small nests or cords”. Nowadays, the World Health Organization (WHO) and the International Society for the Study of Vascular Anomalies (ISSVA) classify EHE as a localized, intrusive and potentially metastasizing vascular tumor[16,17].

Mean age at presentation is 43 years, with the female sex having a slightly higher preponderance than the male sex (1.6 female patients to 1 male patient)[1,13]. In the pediatric population, only 24 cases have been described, with a mean age of 12 years[18]. Liver (21%), bone (14%), and lung (12%) are the most frequent sites of involvement of EHE, but this neoplasm can affect many other sites throughout the body, such as the neck region, the abdominal organs, the genitourinary tract, and also lymph nodes and breast[13].

Exact causes of EHE are still unknown. Tanas *et al*[19] identified WWTR1 (3q25) and CAMTA1 (1p36) as a couple of genes involved in the t(1;3)(p36;q25) chromosomal translocation that is seen in almost every EHE. However, Antonescu *et al*[20] depicted a different group of EHE, which is seen more frequently in younger patients and without sex predilection, that shows a YAP1-TFE3 gene fusion. In addition, another study[21] has proposed the role of chronic Bartonella infection in the pathogenesis of EHE: in fact, the intraerythrocytic and intraendothelial infections, that this microorganism induces, could be linked to the rise of vascular tumors like EHE.

As to the peritoneal form of EHE, the main symptoms are abdominal pain and enlargement, with or without ascites, sometimes associated to nausea, vomiting and weight loss. Our patient reported an intermitting chronic abdominal pain, localized in the lower abdominal quadrants. The recurrent nature of this pain can be explained by the fact that the mass, simulating an ovarian cyst, underwent periodical episodes of blooding, also causing fluid collects. Shiba *et al*[22], in a multicenter retrospective study on 42 Japanese patients, interestingly reported that the presence of symptoms at diagnosis, along with a tumor size greater than 3 cm, were significantly correlated with poor outcomes.

Imaging diagnostic in case of peritoneal EHE usually points out an unclear soft-tissue mass displaying reduced enhancement[23]. It can be associated with signs of invasion of the neighboring structures[13]. Comparison with previous imaging may demonstrate the slow growth rate commonly seen with EHE and less likely to be caused by any other tumor[1]. An omental mass, potentially presenting with tiny implants or wider nodules, is the most typical finding at surgery[12]. In our case, the surgical exploration showed the presence of a peritoneal mass, of augmented consistency, located in the Douglas pouch. Peritoneal carcinomatosis and malignant mesothelioma can easily simulate the aspect of EHE, and because of its rare prevalence, this can lead surgeons to not primarily consider EHE in the differential diagnosis. On the frozen section, the amount of the characteristic round cells with prominent cytoplasmic vacuoles containing erythrocytes is not always significant, but the myxohyaline feature in the stroma can be helpful; the presence of eosinophils is suggestive of EHE, as well[24,25]. Despite the widely infiltrative nature of peritoneal EHE, the single tumor cells generally show only minimal atypia, and the mitotic activity is generally low[12]. Some studies showed that histologic findings of spindle tumor cells and enhanced mitosis (above three mitotic figures per 50 HPF) are associated with worse outcome[1,5,26,27]. The mass of our patient also consisted of a central area of necrosis, vessels of various dimension, intense chronic inflammation with lympho-monocytoid cells, plasma-cells, hystiocytes filled with hemosiderin; no atypic cells were found. Posligua *et al*[12] also suggest the use of electron microscopy in the diagnosis of EHE, because it allows to demonstrate the presence of Weibel-Palade bodies, that have been seen to be more specific for peritoneal EHE, compared to other visceral and soft tissues forms[28].

Immunohistochemistry is an essential part of the diagnostic algorithm, that allows to differentiate primary peritoneal EHE from morphologic pretenders, including carcinoma, mesothelioma of the epithelioid or deciduoid types, peritoneal deciduosis, epithelioid leiomyosarcoma, and malignant gastrointestinal stromal tumor with epithelioid features. In this regard, studies demonstrate that the vascular markers of factor VIII-antigen, CD31, CD34 and thrombomodulin, are very helpful to differentiate EHE from the other tumor types[12].

Because of the variable presentation, course, and outcome of EHE, there is not a standard treatment plan, and the type of therapy must be tailored for every patient[13]. For asymptomatic patients or those with comorbidities precluding treatment, an initial period of observation with repeated clinical and imaging evaluation is recommended to assess the possible progression of the disease[29]. To date, surgical resection represents the most practiced therapeutic option[30] even if few studies[29,31] have shown a reduced response of EHE tumors to the association of conventional chemotherapy and antiangiogenic therapy, which targets vascular endothelial growth factor receptors that are expressed in EHE. In this regard, molecules such as carboplatin, paclitaxel and bevacizumab have been used. Other studies have demonstrated clinical benefits obtained among patients (56%) treated with sirolimus as a single agent[32]. Immune inhibitors are being tested for the treatment of sarcomas and could potentially have a role in the future treatment plan of EHE[33,34] Therapeutic strategies may be developed aiming to WWTR1-CAMTA1 or YAP1-TFE3 mutations, which are common in EHE[19,20].

**CONCLUSION**

EHE is a rare form of sarcoma that can present in any part of the body, and the peritoneal form of EHE often simulates masses of other nature, as in our case. Given its unspecific clinical and radiological presentation, patients are often forced to a large series of tests end examinations before reaching a definitive diagnosis, that can be made only histologically. The possibility of EHE should always be considered in case of slowly growing tumors that invade adjacent organs in the classic sites, as well as in case of unexplained chronic abdominal pain associated to a non-specific neoformation.

**REFERENCES**

1 **Sardaro A**, Bardoscia L, Petruzzelli MF, Portaluri M. Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. *Oncol Rev* 2014; **8**: 259 [PMID: 25992243 DOI: 10.4081/oncol.2014.259]

2 **Rosenberg A**, Agulnik M. Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment. *Curr Treat Options Oncol* 2018; **19**: 19 [PMID: 29546487 DOI: 10.1007/s11864-018-0536-y]

3 **Amin RM**, Hiroshima K, Kokubo T, Nishikawa M, Narita M, Kuroki M, Nakatani Y. Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report. *Respirology* 2006; **11**: 818-825 [PMID: 17052315 DOI: 10.1111/j.1440-1843.2006.00923.x]

4 **Rosengarten D**, Kramer MR, Amir G, Fuks L, Berkman N. Pulmonary epithelioid hemangioendothelioma. *Isr Med Assoc J* 2011; **13**: 676-679 [PMID: 22279701]

5 **Deyrup AT**, Tighiouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. *Am J Surg Pathol* 2008; **32**: 924-927 [PMID: 18551749 DOI: 10.1097/pas.0b013e31815bf8e6]

6 **Kalisher L**, Straatsma GW, Rosenberg BF, Vaitkevicius VK. Primary malignant hemangio- endothelioma of the greater omentum. A case report. *Cancer* 1968; **22**: 1126-1130 [PMID: 5705774 DOI: 10.1002/1097-0142(196811)22:6<1126::AID-CNCR2820220607>3.0.CO;2-2]

7 **Shih SL**, Sheu JC, Chen BF, Ma YC. Malignant hemangioendothelioma presenting as omental masses in a child. *J Pediatr Surg* 1995; **30**: 118-119 [PMID: 7722814 DOI: 10.1016/0022-3468(95)90626-6]

8 **Lin BT**, Colby T, Gown AM, Hammar SP, Mertens RB, Churg A, Battifora H. Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases. *Am J Surg Pathol* 1996; **20**: 1431-1439 [PMID: 8944035 DOI: 10.1097/00000478-199612000-00001]

9 **Attanoos RL**, Dallimore NS, Gibbs AR. Primary epithelioid haemangioendothelioma of the peritoneum: an unusual mimic of diffuse malignant mesothelioma. *Histopathology* 1997; **30**: 375-377 [PMID: 9147089 DOI: 10.1046/j.1365-2559.1997.d01-611.x]

10 **Ratan S**, Bhatnagar V, Gupta SD, Mitra DK. Epithelioid hemangioendothelioma of the greater omentum: report of a case. *Surg Today* 1999; **29**: 919-921 [PMID: 10489137 DOI: 10.1007/BF02482787]

11 **Melzack R**. Phantom limbs. *Sci Am* 1992; **266**: 120-126 [PMID: 1566028 DOI: 10.1007/s00428-004-1136-8]

12 **Posligua L**, Anatelli F, Dehner LP, Pfeifer JD. Primary peritoneal epithelioid hemangioendothelioma. *Int J Surg Pathol* 2006; **14**: 257-267 [PMID: 16959716 DOI: 10.1177/1066896906290682]

13 **Jang JK**, Thomas R, Braschi-Amirfarzan M, Jagannathan JP. A Review of the Spectrum of Imaging Manifestations of Epithelioid Hemangioendothelioma. *AJR Am J Roentgenol* 2020; **215**: 1290-1298 [PMID: 32841059 DOI: 10.2214/AJR.20.22876]

14 **Dail D,** Liebow AA. Intravascular bronchioloalveolar tumor. *Am J Pathol* 1975; **78**: 6a–7a

15 **Weiss SW**, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. *Cancer* 1982; **50**: 970-981 [PMID: 7093931 DOI: 10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z]

16 **Merrow AC**, Gupta A, Patel MN, Adams DM. 2014 Revised Classification of Vascular Lesions from the International Society for the Study of Vascular Anomalies: Radiologic-Pathologic Update. *Radiographics* 2016; **36**: 1494-1516 [PMID: 27517361 DOI: 10.1148/rg.2016150197]

17 **Sepulveda A**, Buchanan EP. Vascular tumors. *Semin Plast Surg* 2014; **28**: 49-57 [PMID: 25045329 DOI: 10.1055/s-0034-1376260]

18 **Cousin S**, Le Loarer F, Crombé A, Karanian M, Minard-Colin V, Penel N. [Epithelioid hemangioendothelioma]. *Bull Cancer* 2019; **106**: 73-83 [PMID: 30527817 DOI: 10.1016/j.bulcan.2018.11.004]

19 **Tanas MR**, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, Flanagan J, Luo Y, Fenwick K, Natrajan R, Mitsopoulos C, Zvelebil M, Hoch BL, Weiss SW, Debiec-Rychter M, Sciot R, West RB, Lazar AJ, Ashworth A, Reis-Filho JS, Lord CJ, Gerstein MB, Rubin MA, Rubin BP. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. *Sci Transl Med* 2011; **3**: 98ra82 [PMID: 21885404 DOI: 10.1126/scitranslmed.3002409]

20 **Antonescu CR**, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M, Fletcher CD. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. *Genes Chromosomes Cancer* 2013; **52**: 775-784 [PMID: 23737213 DOI: 10.1002/gcc.22073]

21 **Mascarelli PE**, Iredell JR, Maggi RG, Weinberg G, Breitschwerdt EB. Bartonella species bacteremia in two patients with epithelioid hemangioendothelioma. *J Clin Microbiol* 2011; **49**: 4006-4012 [PMID: 21918021 DOI: 10.1128/JCM.05527-11]

22 **Shiba S**, Imaoka H, Shioji K, Suzuki E, Horiguchi S, Terashima T, Kojima Y, Okuno T, Sukawa Y, Tsuji K, Umemoto K, Asagi A, Todaka A, Ueno M, Ikeda M, Morizane C, Furuse J. Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. *BMC Cancer* 2018; **18**: 993 [PMID: 30340559 DOI: 10.1186/s12885-018-4934-0]

23 **Epelboym Y**, Engelkemier DR, Thomas-Chausse F, Alomari AI, Al-Ibraheemi A, Trenor CC 3rd, Adams DM, Chaudry G. Imaging findings in epithelioid hemangioendothelioma. *Clin Imaging* 2019; **58**: 59-65 [PMID: 31238187 DOI: 10.1016/j.clinimag.2019.06.002]

24 **Hamlat A**, Casallo-Quilliano C, Saikali S, Lesimple T, Brassier G. Epithelioid hemangioendothelioma of the infundibular-hypothalamic region: case report and literature review. *J Neurooncol* 2004; **67**: 361-366 [PMID: 15164993 DOI: 10.1023/b:neon.0000024240.97378.d0]

25 **Pinet C**, Magnan A, Garbe L, Payan MJ, Vervloet D. Aggressive form of pleural epithelioid haemangioendothelioma: complete response after chemotherapy. *Eur Respir J* 1999; **14**: 237-238 [PMID: 10489858 DOI: 10.1034/j.1399-3003.1999.14a40.x]

26 **Kitaichi M**, Nagai S, Nishimura K, Itoh H, Asamoto H, Izumi T, Dail DH. Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. *Eur Respir J* 1998; **12**: 89-96 [PMID: 9701420 DOI: 10.1183/09031936.98.12010089]

27 **Schmoldt A,** Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. *Biochem Pharmacol* 1975; **24**: 1639-1641 [DOI: 10.1016/0006-2952(75)90094-5]

28 **Tsuneyoshi M**, Dorfman HD, Bauer TW. Epithelioid hemangioendothelioma of bone. A clinicopathologic, ultrastructural, and immunohistochemical study. *Am J Surg Pathol* 1986; **10**: 754-764 [PMID: 2430475 DOI: 10.1097/00000478-198611000-00002]

29 **Yousaf N**, Maruzzo M, Judson I, Al-Muderis O, Fisher C, Benson C. Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. *Anticancer Res* 2015; **35**: 473-480 [PMID: 25550590]

30 **Wu X**, Li B, Zheng C, Hong T, He X. Clinical characteristics of epithelioid hemangioendothelioma: a single-center retrospective study. *Eur J Med Res* 2019; **24**: 16 [PMID: 30819247 DOI: 10.1186/s40001-019-0375-8]

31 **Belmont L**, Zemoura L, Couderc LJ. Pulmonary epithelioid haemangioendothelioma and bevacizumab. *J Thorac Oncol* 2008; **3**: 557-558 [PMID: 18449015 DOI: 10.1097/JTO.0b013e31816e2400]

32 **Stacchiotti S**, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, Casali PG. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. *Ann Surg Oncol* 2016; **23**: 2735-2744 [PMID: 27334221 DOI: 10.1245/s10434-016-5331-z]

33 **Veenstra R**, Kostine M, Cleton-Jansen AM, de Miranda NF, Bovée JV. Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. *Lab Invest* 2018; **98**: 41-50 [PMID: 29155424 DOI: 10.1038/labinvest.2017.128]

34 **Thomas R**, Somarouthu B, Alessandrino F, Kurra V, Shinagare AB. Atypical Response Patterns in Patients Treated With Nivolumab. *AJR Am J Roentgenol* 2019: 1-5 [PMID: 30917022 DOI: 10.2214/AJR.18.20938]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** All authors report no relevant conflict of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016)

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 18, 2022

**First decision:** August 1, 2022

**Article in press:** November 23, 2022

**Specialty type:** Oncology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Paparoupa M, Germany; Tong Y, China **S-Editor:** Wu YXJ **L-Editor:** A **P-Editor:** Wu YXJ

**Figure Legends**



**Figure 1 Magnetic resonance imaging scan showing the mass simulating an ovarian cyst (arrows).**



**Figure 2 Histopathological analysis and immunohistochemical examination of the resected specimen.** A-F: Vascular lesion composed of circumscribed proliferation of blood vessels with different size and caliber. The thin of the wall is different in the different vassells. Necrosis and degenerative aspects are associated with lympho-monocitoid and plasmacell infiltration. The presence of macrophages with hemosiderin is evident (black arrow) (magnification 2×).

**Table 1 Cases of peritoneal epithelioid hemangioendothelioma reported in the literature**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Journal** | **Number of cases** | **Average age** | **Sex** | **Treatment** |
| Kalisher *et al*[6], 1968 | *Cancer* | 1 | 30 | F | Surgery |
| Shih *et al*[7], 1995 | *J Pediatr Surg* | 1 | 13 | F | Surgery |
| Lin *et al*[8], 1996 | *Am J Surg Pathol* | 3 | 52 | 2 F;  1 M | Surgery |
| Attanoos *et al*[9], 1997 | *Histopathology* | 1 | 51 | M | Surgery |
| Ratan *et al*[10], 1999 | *Surg Today* | 1 | 11 | F | Surgery |
| Melzack *et al*[11], 2004 | *Virchows Arch* | 2 | 28.5 | 2 M | Surgery |
| Posligua *et al*[12], 2006 | *Int J Surg Pathol* | 3 | 45.6 | 2 M;  1 F | Surgery |
| **Total** |  | **12** | **19.2** | **6 F;**  **6 M** |  |

F: Female; M: Male.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**